Evidence map›Paper›PMID 41024279›Full record

ReviewActa neuropathologica communications2025

Current states in understanding oligodendroglia-mediated neurological issues in neurofibromatosis type 1 (NF1).

Benjamin E Aghoghovwia, Cheng-En Shen, Sabiha Bano, Nandini Shyamala, Alesandra Echeandia Marrero, Khushboo Irshad, Samer Sharafaldin, Nicole M Brossier, Yuan Pan

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta neuropathologica communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Benjamin E AghoghovwiaDepartment of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Cheng-En ShenDepartment of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sabiha BanoDepartment of Pediatrics, Washington University in St Louis, St Louis, MO, USA.
Nandini ShyamalaDepartment of Pediatrics, Washington University in St Louis, St Louis, MO, USA.
Alesandra Echeandia MarreroDepartment of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Khushboo IrshadDepartment of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Samer SharafaldinDepartment of Health and Human Performance, University of Houston, Houston, TX, USA.
Nicole M BrossierDepartment of Pediatrics, Washington University in St Louis, St Louis, MO, USA.
Yuan PanDepartment of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ypan4@mdanderson.org.

Funding

Cancer Prevention and Research Institute of Texas RR210085Eunice Kennedy Shriver National Institute of Child Health and Human Development K12HD076244Gilbert Family Foundation 622030Neurofibromatosis Therapeutic Acceleration Program 210112U.S. Department of Defense HT9425-23-1-0239
6 · The paper itself

Abstract

Neurofibromatosis type 1 (NF1) is among the most common neurogenetic disorders and is associated with an increased risk of developing tumors in the nervous system. Additionally, up to 80% of patients with NF1 experience neurological complications, including deficits in attention, memory, and executive function. Significant effort has been dedicated to studying how NF1 mutations autonomously dysregulate neuronal function. Increasing evidence indicates that NF1 mutations also dysregulate the oligodendroglial lineage that contributes to neurological issues in NF1. Here, we summarize our current understanding of how NF1 mutations impact the oligodendroglial lineage homeostasis and plasticity. We also discuss gaps in knowledge, potential therapeutic strategies, and future directions.

Indexed as

Neurofibromatosis 1OligodendrogliaAnimalsHumansMutationNeurofibromin 1Neurofibromin 1GliomasNeurofibromatosis type 1Neuron-OPC crosstalkOligodendroglial lineageOligodendroglial plasticity

Identifiers

PMID41024279
PMCPMC12482478

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.